Biogerontology

UM School of Medicine Receives Award for Research on Aging and Cognitive Function

Retrieved on:

Thursday, June 24, 2021

The Dr. M. Lee Pearce Foundation, Inc., established in 1984, has announced a donation to the University of Miamis School of Medicine in support of its research on aging and cognitive function.

Key Points:

The Dr. M. Lee Pearce Foundation, Inc., established in 1984, has announced a donation to the University of Miamis School of Medicine in support of its research on aging and cognitive function.
The funding of the research study Epigenetic Clock as a Fountain of Youth: Is the Epigenetic Age more Important for Cognitive Function than Chronological Age?
is part of the foundations mission to fund breakthrough research with an emphasis on aging.
The UM study will further assess how the epigenetic clock, or biological age, can be affected by behaviors such as diet, exercise, and environment.

Extended Longevity Announces New Study to Provide Additional Data for Its Profound Biological Age Reversal Protocol

Retrieved on:

Thursday, June 3, 2021

The study is entitled Longevinaut Study #1: The Safety and Effectiveness of the Extended Longevity Protocol on the Epigenetic Aging Rate in Healthy Individuals.

Key Points:

The study is entitled Longevinaut Study #1: The Safety and Effectiveness of the Extended Longevity Protocol on the Epigenetic Aging Rate in Healthy Individuals.
Epigenetic age is measured by DNA methylation and is considered by many to be the most exact measure of a person's biological age.
"The data we've been gathering is showing age reversal at a level not being reported by anyone else," Extended Longevity Founder and CEO, Steven M. Schorr, explained.
In addition to reducing epigenetic age, the Extended Longevity protocol has demonstrated other results revealing profound age deceleration, including decreased inflammation to optimal levels and extended telomere length akin to that of a 10-year-old.

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

Retrieved on:

Tuesday, March 2, 2021

Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, AgeX Therapeutics, Biogerontology, Mergers and acquisitions, Economy, Articles, Academic disciplines, the Proposed Merger, AgeX Therapeutics, LyGenesis, Inc

AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies.

Key Points:

AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies.
Dr. Michael Hufford, who is the current Chief Executive Officer (CEO) of LyGenesis, upon successful merger would become CEO of the entity that survives the transaction (which includes both AgeX and LyGenesis).
There can be no assurance that the negotiations between AgeX and LyGenesis will result in the execution of a definitive merger agreement on the terms being discussed or at all, or, if a merger agreement is entered into, that the merger will be consummated.
Further, the potential merger with LyGenesis is subject to additional risks and uncertainties, including (i) negotiation of a definitive merger agreement, (ii) approval of a merger agreement by the respective boards of directors of AgeX and LyGenesis, (iii) approval of the merger agreement by AgeX stockholders, (iv) the satisfaction or waiver of such contractual conditions to the merger as may be included in the merger agreement, (v) the ability of AgeX and LyGenesis to raise additional capital for the merged company, (vi) potential difficulties integrating the business practices and operations of AgeX with the business practices and operations of LyGenesis; including potential difficulties in conforming accounting policies, procedures, internal controls, and financial records of LyGenesis with AgeX, (vii) the uncertain expense and outcome of the planned clinical trial of LyGenesis liver failure treatment, (viii) the cost and risks associated with the development of additional cell therapies in the LyGenesis product pipeline, (ix) unexpected expenditures or assumed liabilities that may be incurred as a result of the merger, (x) inability to accurately forecast the performance of LyGenesis and AgeX as an integrated company, and (xii) expected synergies between LyGenesis and AgeX may be materially different from actual results.

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Retrieved on:

Friday, June 5, 2020

Science, Cardiology, Stem cells, Biotechnology, Research, Pharmaceutical, Health, Diabetes, AgeX Therapeutics, Biogerontology, Economy of the United States, Intercontinental Exchange, NYSE American, Listing, New York Stock Exchange, States of the United States, United States, Life extensionists

AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the Exchange) indicating that AgeX does not meet certain of the Exchanges continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years.

Key Points:

AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the Exchange) indicating that AgeX does not meet certain of the Exchanges continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years.
Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX intends to provide the Exchange staff with a plan by July 1, 2020 advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchanges continued listing standards by December 1, 2021.
If the Exchange staff does not accept AgeXs plan, the Exchange staff will promptly initiate delisting proceedings.
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer

Retrieved on:

Thursday, May 21, 2020

Biotechnology, Pharmaceutical, Health, AgeX Therapeutics, Biogerontology, California, Stem cells, Lineage Cell Therapeutics, States of the United States, Life extensionists

AgeX Therapeutics , Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer.

Key Points:

AgeX Therapeutics , Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer.
Ms. Park replaces Russell Skibsted who served in that role since the Company was organized in 2017.
Andrea Park served as our Vice President of Finance and Controller since October 2019.
Before joining AgeX, she served as Vice President of Finance and Controller of Lineage Cell Therapeutics, Inc.

AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells

Retrieved on:

Friday, February 28, 2020

Biotechnology, Genetics, Health, Clinical trials, Stem cells, Biotechnology, Branches of biology, AgeX Therapeutics, Biogerontology, Biology, Induced stem cells, Induced pluripotent stem cell

The senior author is Dana Larocca, PhD, VP of Discovery Research at AgeX, and the first author is Jieun Lee, PhD, Scientist at AgeX.

Key Points:

The senior author is Dana Larocca, PhD, VP of Discovery Research at AgeX, and the first author is Jieun Lee, PhD, Scientist at AgeX.
The paper notes that the supercentenarians cells reverted to induced pluripotent stem (iPS) cells at the same rate as the HDC subject and the Progeria patient.
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

Retrieved on:

Wednesday, January 29, 2020

AgeX Therapeutics, Inc. ( AgeX ; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeXs HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

Key Points:

AgeX Therapeutics, Inc. ( AgeX ; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeXs HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.
The research program will evaluate the expression of UniverCyte on induced pluripotent stem cells (iPS cells) and the ability of those UniverCyte-modified iPS cells to evade immune responses and to differentiate into somatic cells.
AgeX hopes to announce further collaborations for research and product development utilizing its technology platforms in the coming months.
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

AgeX Therapeutics to Participate at Four Conferences in January 2020

Retrieved on:

Tuesday, January 14, 2020

Research, Medical devices, Diabetes, Clinical trials, Cardiology, Stem cells, Biotechnology, Pharmaceutical, Health, Science, Biogerontology, AgeX Therapeutics, Immunogenicity, Life extensionists, Medicine, Health, Economy of the United States

AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase , January 13-15; Precision Medicine World Conference ( PMWC 2020 ), January 21-24; World Stem Cell Summit , January 21-24; and Longevity Therapeutics , January 28-30.

Key Points:

AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase , January 13-15; Precision Medicine World Conference ( PMWC 2020 ), January 21-24; World Stem Cell Summit , January 21-24; and Longevity Therapeutics , January 28-30.
AgeX will participate in a 90-minute session that will include two talks as well as a panel discussion, on Thursday, January 23, 1:45-3:15pm EST.
Additionally, three AgeX team members will participate on a panel discussion, The next stem cell revolution: transcending limits on purity, immunogenicity and oncogenicity.
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

AgeX Therapeutics Issues Year-End Letter to Shareholders

Retrieved on:

Monday, December 9, 2019

AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress made in AgeXs first year as a public company, as well as current initiatives and future plans.

Key Points:

AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress made in AgeXs first year as a public company, as well as current initiatives and future plans.
Our belief is that this is about to change through harnessing the power of new cellular and molecular technologies.
We established our own accounting and administration capabilities, and ended our shared facilities and services agreement with Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.).
We appreciate your support and the dedication of our scientists and employees as we forge a new future for medicine.

The Bia-Echo Foundation announces the Global Consortium for Female Reproductive Longevity and Equality in partnership with the Buck Institute for Research on Aging

Retrieved on:

Monday, September 30, 2019

California, Demography, States of the United States, Biogerontology, Buck Institute for Research on Aging, Longevity, Novato, California, Ageing

NOVATO, Calif., Sept. 30, 2019 /PRNewswire/ -- The Bia-Echo Foundation and the Buck Institute for Research on Aging today announced the formation of the Global Consortium for Female Reproductive Longevity and Equality.

Key Points:

NOVATO, Calif., Sept. 30, 2019 /PRNewswire/ -- The Bia-Echo Foundation and the Buck Institute for Research on Aging today announced the formation of the Global Consortium for Female Reproductive Longevity and Equality.
The Consortium will be anchored at the Buck's Center for Female Reproductive Longevity and Equality which was established in 2018 with a gift from attorney and entrepreneur Nicole Shanahan.
With the Buck Center for Female Reproductive Longevity and Equality at its center, leading novel research and core research functions and hosting a biannual global meeting, the Global Consortium will empower scientists worldwide to participate in this emerging field.
"Igniting the science within longevity research and with a purpose towards equity is something I'm thrilled to do in partnership with the Buck Institute."